HCC

>

Latest News

First-Line Nivolumab/Ipilimumab Improves Survival in Hepatocellular Cancer
First-Line Nivolumab/Ipilimumab Improves Survival in Hepatocellular Cancer

March 20th 2024

Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma

February 15th 2024

Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC

February 6th 2024

FDA Fast Tracks BST02 for Liver Cancer
FDA Fast Tracks BST02 for Liver Cancer

February 2nd 2024

More News